Jeanmarie Guenot: Scientist, Researcher And Business Executive

 

Dr. Jeanmarie Guenot is a scientist and businesswoman. She’s currently Amphivena Therapeutics president and CEO (http://amphivena.com/amphivena_leaders/jeanmarie-guenot-ph-d/). The company develops innovative bifunctional antibody therapies that can be used to treat hematologic malignancies. Since earning her MBA from the University of Pennsylvania’s The Wharton School and her PhD. from UC San Francisco, Guenot has spent more than 20 years working in the biotechnology and pharmaceutical industries. She has experience in business development, pharmaceutical research and development, project and alliance management, corporate and commercial development and venture capital.

 

Her biography shows that Guenot has worked with public and private companies at all stages of development. She also has a great deal of experience and a strong interest in creating and rebuilding companies. Prior to working with Amphivena Therapeutics, Guenot founded, developed and ran the start-up ophthalmic company incubator, SKS Ocular. The company’s work was focused on dry AMD as well as the delivery technologies and therapeutics for sustained release ocular drugs used for macular degeneration, glaucoma and ocular inflammation.

 

A former Hoffmann-La Roche business advisor, Jeanmarie Guenot was also PDL Biopharma’s VP of Corporate and Business Development. At the company she led mergers and acquisitions, licensing and alliance management for research and development as well as commercial product portfolios. Guenot also negotiated the co-development as well as the co-commercialization strategic collaboration of Biogen Idec-PDL 50:50. This involved three Phase 2 autoimmune disease and cancer drug candidates. This transaction was valued at $800 million and included an equity investment of $100 million in PDL as well as a therapeutic candidate and its indications which were split between Hoffmann-La Roche and Biogen Idec/PDL.

 

CrunchBase.com writes that Guenot was involved in the licensing to Ophthotech of the oncology drug’s ophthalmic indication. She has experience in project, portfolio and alliance management in cardiovascular diseases, autoimmune diseases, oncology, neurology and ophthalmic diseases. At the beginning of her business career Guenot managed Atlas Venture’s capital investments and built life science companies for them. Her work as a scientist began with her becoming a Hoffmann-La Roche principal scientist working on preclinical research and development, discovering and developing drugs to treat autoimmune diseases, metabolic diseases, inflammation and oncology.  Read more about Jeanmarie Guenot, and her efforts with Amphivena cancer research on BusinessWire.